Metabolic dysfunction-associated steatotic liver disease (MASLD) is the updated nomenclature for the entity previously called nonalcoholic fatty liver disease (NAFLD). The 2023 name change reflects a focus on metabolic dysfunction as the underlying driver of hepatic steatosis. The reviewed article is intended as a primer for primary care nurse practitioners (NPs) and frames MASLD as a common condition with potential for serious sequelae.
The source characterizes MASLD as highly prevalent globally, underscoring its public health importance. The abstract notes that MASLD can affect broad populations and that prevalence and burden are topics addressed in the review. Precise prevalence estimates, trends by region or age, and numerical burden metrics were not reported in the abstract and require consultation of the full article or cited epidemiologic references for details.
The review summarizes pathophysiology as a topic covered in the article. MASLD is linked to metabolic dysfunction, and a subset of patients progress to metabolic dysfunction–associated steatohepatitis (MASH), which can produce clinically significant hepatic fibrosis. The abstract indicates that pathophysiologic mechanisms are discussed but does not provide mechanistic details in the abstract text itself.
The article addresses differential diagnosis for patients with hepatic steatosis in primary care. MASLD can be encountered during routine evaluation of patients with metabolic disorder features. The abstract signals that primary care clinicians should consider differential diagnoses when evaluating suspected MASLD. Specific signs, symptoms, or differential conditions were not enumerated in the abstract and would be found in the full text.
According to the abstract, some patients with MASLD can be managed and followed in primary care. This implies that initial recognition, risk assessment, and noninvasive evaluation are within the scope of primary care practice. However, the abstract does not list the diagnostic tests, scoring systems, imaging strategies, or monitoring intervals; those specifics are likely covered in the full review and should be consulted for practice implementation.
The abstract explicitly states that patients with clinically significant fibrosis from metabolic dysfunction–associated steatohepatitis (MASH) should be managed in specialty care. This establishes a clear triage principle: primary care manages lower-risk MASLD, whereas confirmed or suspected MASH with significant fibrosis warrants hepatology or specialty referral. The abstract does not define thresholds for “clinically significant fibrosis” or the precise referral triggers used; readers should review the full article for recommended criteria and referral pathways.
Management of MASLD is a central topic of the review. The abstract conveys that the article addresses management strategies that can be applied in primary care and delineates when specialty management is appropriate. Specific therapeutic recommendations, pharmacologic options, lifestyle interventions, or monitoring plans are not detailed in the abstract and therefore are not restated here. For actionable management protocols and medication guidance, consult the full text and guideline sources cited by the review.
The abstract identifies the review’s scope—pathophysiology, differential diagnosis, and management—but does not present granular clinical protocols or numeric guidance. Clinicians seeking detailed diagnostic algorithms, fibrosis staging thresholds, or treatment regimens should access the full article and its referenced literature. The review’s bibliography (74 references listed in the PubMed entry) can direct readers to epidemiologic studies, diagnostic research, and management guidelines for MASLD and MASH.
Note on available information
This summary is based solely on the abstract text provided. The abstract describes the topics covered and the high-level clinical conclusions about primary care roles and the need for specialty referral for MASH with clinically significant fibrosis, but it does not include specific diagnostic tests, staging cutoffs, therapeutic regimens, or procedural details. Those items were not reported in the abstract and require the full article for complete clinical guidance.